CN113226314B - 吡咯烷化合物的晶体 - Google Patents

吡咯烷化合物的晶体 Download PDF

Info

Publication number
CN113226314B
CN113226314B CN201980086473.9A CN201980086473A CN113226314B CN 113226314 B CN113226314 B CN 113226314B CN 201980086473 A CN201980086473 A CN 201980086473A CN 113226314 B CN113226314 B CN 113226314B
Authority
CN
China
Prior art keywords
crystals
crystal
pyrrolidine
phosphoric acid
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980086473.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN113226314A (zh
Inventor
上田直子
长田裕臣
吉田琢纮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Priority to CN202510225181.6A priority Critical patent/CN120081827A/zh
Priority to CN202510224370.1A priority patent/CN120081826A/zh
Publication of CN113226314A publication Critical patent/CN113226314A/zh
Application granted granted Critical
Publication of CN113226314B publication Critical patent/CN113226314B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201980086473.9A 2018-12-28 2019-12-27 吡咯烷化合物的晶体 Active CN113226314B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202510225181.6A CN120081827A (zh) 2018-12-28 2019-12-27 吡咯烷化合物的晶体
CN202510224370.1A CN120081826A (zh) 2018-12-28 2019-12-27 吡咯烷化合物的晶体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-247437 2018-12-28
JP2018247437 2018-12-28
PCT/JP2019/051570 WO2020138481A1 (ja) 2018-12-28 2019-12-27 ピロリジン化合物の結晶

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202510225181.6A Division CN120081827A (zh) 2018-12-28 2019-12-27 吡咯烷化合物的晶体
CN202510224370.1A Division CN120081826A (zh) 2018-12-28 2019-12-27 吡咯烷化合物的晶体

Publications (2)

Publication Number Publication Date
CN113226314A CN113226314A (zh) 2021-08-06
CN113226314B true CN113226314B (zh) 2025-03-18

Family

ID=71127176

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201980086473.9A Active CN113226314B (zh) 2018-12-28 2019-12-27 吡咯烷化合物的晶体
CN202510224370.1A Pending CN120081826A (zh) 2018-12-28 2019-12-27 吡咯烷化合物的晶体
CN202510225181.6A Pending CN120081827A (zh) 2018-12-28 2019-12-27 吡咯烷化合物的晶体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202510224370.1A Pending CN120081826A (zh) 2018-12-28 2019-12-27 吡咯烷化合物的晶体
CN202510225181.6A Pending CN120081827A (zh) 2018-12-28 2019-12-27 吡咯烷化合物的晶体

Country Status (8)

Country Link
US (2) US12077524B2 (enExample)
EP (3) EP4603143A3 (enExample)
JP (3) JP6977185B2 (enExample)
CN (3) CN113226314B (enExample)
ES (1) ES2991904T3 (enExample)
MA (1) MA54619A (enExample)
TW (3) TWI834791B (enExample)
WO (1) WO2020138481A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI882128B (zh) * 2020-06-10 2025-05-01 日商田邊三菱製藥股份有限公司 紫質症之預防或治療劑
BR112022025115A2 (pt) 2020-06-10 2023-02-07 Mitsubishi Tanabe Pharma Corp Agente profilático ou terapêutico para fotodermatose
JP6959478B1 (ja) * 2020-06-10 2021-11-02 田辺三菱製薬株式会社 ポルフィリン症の予防又は治療剤
EP4317150A4 (en) * 2021-05-06 2024-10-30 Lg Chem, Ltd. CRYSTAL FORM VII OF A MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD FOR THE PREPARATION THEREOF
KR102854595B1 (ko) * 2021-05-06 2025-09-03 주식회사 엘지화학 멜라노코르틴 수용체 작용제 화합물의 결정형 v 및 이의 제조방법
MX2023013128A (es) * 2021-05-07 2023-11-28 Lg Chemical Ltd Cristales de sulfato de compuesto agonista del receptor de melanocortina, y metodo para producir los mismos.
CA3217468A1 (en) * 2021-05-07 2022-11-10 Lg Chem, Ltd. Crystal form iv of organic acid salts of melanocortin receptor agonist compound, and preparation method thereof
JP2024516739A (ja) * 2021-05-07 2024-04-16 エルジー・ケム・リミテッド メラノコルチン受容体アゴニスト化合物とバニリンの共結晶およびその製造方法
EP4473967A4 (en) 2022-01-31 2025-10-08 Mitsubishi Tanabe Pharma Corp NOVEL USE OF A MELANOCORTIN-1 RECEPTOR AGONIST
JP7527582B2 (ja) * 2022-08-03 2024-08-05 田辺三菱製薬株式会社 １－｛２－［（３ｓ，４ｒ）－１－｛［（３ｒ，４ｒ）－１－シクロペンチル－３－フルオロ－４－（４－メトキシフェニル）ピロリジン－３－イル］カルボニル｝－４－（メトキシメチル）ピロリジン－３－イル］－５－（トリフルオロメチル）フェニル｝ピペリジン－４－カルボン酸もしくはその医薬的に許容し得る塩又は共結晶を含有する医薬組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106458887A (zh) * 2014-05-29 2017-02-22 田边三菱制药株式会社 新型吡咯烷化合物及作为黑皮质素受体激动剂的用途
JP2017105765A (ja) * 2015-11-27 2017-06-15 田辺三菱製薬株式会社 医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006030925A1 (ja) * 2004-09-13 2006-03-23 Ono Pharmaceutical Co., Ltd. 含窒素複素環誘導体およびそれらを有効成分とする薬剤
JP2009510134A (ja) * 2005-10-07 2009-03-12 ワラタ ファーマシューティカルズ， インコーポレイテッド Ｄｐｐ−ｉｖ阻害剤およびガストリン化合物の組み合わせ使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106458887A (zh) * 2014-05-29 2017-02-22 田边三菱制药株式会社 新型吡咯烷化合物及作为黑皮质素受体激动剂的用途
JP2017105765A (ja) * 2015-11-27 2017-06-15 田辺三菱製薬株式会社 医薬組成物

Also Published As

Publication number Publication date
US20220073497A1 (en) 2022-03-10
TW202517631A (zh) 2025-05-01
CN113226314A (zh) 2021-08-06
TW202421621A (zh) 2024-06-01
EP3903785A4 (en) 2022-08-10
WO2020138481A1 (ja) 2020-07-02
CN120081827A (zh) 2025-06-03
CN120081826A (zh) 2025-06-03
JP7652682B2 (ja) 2025-03-27
US12077524B2 (en) 2024-09-03
EP4603143A3 (en) 2025-11-05
ES2991904T3 (es) 2024-12-05
EP4603143A2 (en) 2025-08-20
US20250002474A1 (en) 2025-01-02
TWI834791B (zh) 2024-03-11
TW202039464A (zh) 2020-11-01
EP3903785A1 (en) 2021-11-03
JPWO2020138481A1 (ja) 2021-09-27
JP2022024034A (ja) 2022-02-08
JP6977185B2 (ja) 2021-12-08
EP4434582A2 (en) 2024-09-25
EP3903785B1 (en) 2024-10-02
EP4434582A3 (en) 2024-12-18
MA54619A (fr) 2021-11-03
TWI870228B (zh) 2025-01-11
JP2025085744A (ja) 2025-06-05

Similar Documents

Publication Publication Date Title
CN113226314B (zh) 吡咯烷化合物的晶体
US8501753B2 (en) Useful pharmaceutical salts of 7-[(3R, 4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3, 5-dihydro-pyrrolo [3, 2-D] pyrimidin-4-one
CN105209437B (zh) 心肌肌球蛋白激动剂的盐和制备盐的方法
US10023577B2 (en) Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof
EP3205653B1 (en) Crystal form of bisulfate of jak inhibitor and preparation method therefor
JP2024525254A (ja) ウロデシン塩
JP2017530107A (ja) ナトリウム・グルコース共輸送体２阻害薬のｌ−プロリン化合物、およびｌ−プロリン化合物の一水和物および結晶
JP2015534989A (ja) ｛ｓ−３−（４−アミノ−１−オキソ−イソインドリン−２−イル）（ピペリジン−３，４，４，５，５−ｄ５）−２，６−ジオン｝の固体形態
JP2015536316A (ja) Ｌ‐リジンを含む（３ｓ，３ｓ’）４，４’‐ジスルファンジイルビス（３‐アミノブタン１‐スルホン酸）の新規結晶相
CN113929630B (zh) 一种吉非替尼药物共晶体
CN116178277A (zh) 氯比普兰甲磺酸盐晶型及其制备方法
WO2023061372A1 (zh) 占诺美林衍生物的苹果酸盐、a晶型及其制备方法和用途
CN116239522A (zh) 一种米力农-丁二酸共晶体
CN116283958A (zh) 唑吡坦共晶体及其制备方法
CN114671826A (zh) 一种莫沙必利有机酸晶体
JP2021505602A (ja) 腎外髄質カリウムチャネル阻害剤の結晶形およびその調製方法
BRPI0904938A2 (pt) método de obtenção de um co-cristal de lamivudina, seu sal maleato, formulações farmacêuticas e seu uso

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant